{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:43:46Z","timestamp":1774543426875,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012631","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000}}],"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Patients with an active cancer are more likely to develop melioidosis, but the characteristics and clinical course of melioidosis in patients with cancer have not been examined in detail. Trimethoprim\/sulfamethoxazole (TMP-SMX) prophylaxis is prescribed to prevent melioidosis in patients receiving immune suppressing anti-cancer therapy in some jurisdictions\u2013and is recommended in national Australian guidelines\u2013however the risks and benefits of this strategy are incompletely defined.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study took place in Far North Queensland (FNQ) in tropical Australia. The characteristics and clinical course of patients with melioidosis diagnosed in the FNQ region between January 1, 1998, and June 1, 2023, who had\u2013and did not have\u2013an active cancer were compared. We also determined the subsequent incidence of melioidosis in patients receiving immune suppressing anti-cancer therapy in the FNQ region between January 1, 2008, and June 1, 2023, who did\u2013and did not\u2013receive TMP-SMX chemoprophylaxis for <jats:italic>Pneumocystis jirovecii<\/jats:italic> infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>An active cancer was present in 47\/446 (11%) cases of melioidosis diagnosed between January 1, 1998, and June 1, 2023; there was no association between melioidosis and any cancer type. Patients with melioidosis and cancer were more likely to be older (odds ratio (OR) (95% confidence interval (CI): 1.05 (1.03\u20131.08) P&lt;0.0001) and immunosuppressed (OR (95% CI): 11.54 (5.41\u201324.6), p&lt;0.0001) than patients without cancer. Immune suppressing anti-cancer therapy had been prescribed to 17\/47 (36%) in the 12 months prior to their diagnosis of melioidosis. Only 10\/47 (21%) with cancer and melioidosis in the cohort had received no immune suppressing anti-cancer therapy and had no other risk factors for melioidosis. Twelve months after the diagnosis of melioidosis, 25\/47 (53%) were still alive; 9\/22 (41%) deaths were due to melioidosis and 13\/22 (59%) were due to the underlying cancer.<\/jats:p>\n<jats:p>Between 2008 and June 2023, there were 4400 individuals who received myelosuppressive anti-cancer therapy in the FNQ region. There was no significant difference in the incidence of melioidosis between patients who did\u2013and did not\u2013receive TMP-SMX chemoprophylaxis with their myelosuppressive anti-cancer therapy (1\/737 (0.15%) versus 16\/3663 (0.44%); relative risk (95% confidence interval): 0.31 (0.04\u20132.34), p = 0.20) and no significant difference in the incidence of fatal melioidosis (0\/737 versus 3\/3663 (0.08%), p = 0.58).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Patients with cancer are predisposed to developing melioidosis and immune suppressing anti-cancer therapy increases this risk further. However, in this region of Australia, there was no significant difference in the subsequent development of melioidosis in patients who did\u2013and did not\u2013receive TMP-SMX chemoprophylaxis during their myelosuppressive anti-cancer therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0012631","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:39:19Z","timestamp":1729877959000},"page":"e0012631","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["The characteristics and clinical course of patients with melioidosis and cancer"],"prefix":"10.1371","volume":"18","author":[{"given":"Tej","family":"Shukla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristoffer","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Donald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-3839","authenticated-orcid":true,"given":"Josh","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"pntd.0012631.ref001","article-title":"Burkholderia pseudomallei and melioidosis","author":"EM Meumann","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"pntd.0012631.ref002","doi-asserted-by":"crossref","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"D Limmathurotsakul","year":"2016","journal-title":"Nat Microbiol"},{"issue":"1","key":"pntd.0012631.ref003","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1371\/journal.pntd.0000364","article-title":"Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia","volume":"3","author":"M Kaestli","year":"2009","journal-title":"PLoS neglected tropical diseases"},{"issue":"5","key":"pntd.0012631.ref004","doi-asserted-by":"crossref","first-page":"e0000506","DOI":"10.1371\/journal.pgph.0000506","article-title":"The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens","volume":"2","author":"LJ Fairhead","year":"2022","journal-title":"PLOS Global Public Health"},{"key":"pntd.0012631.ref005","article-title":"A call to action: time to recognise melioidosis as a neglected tropical disease","author":"J Savelkoel","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0012631.ref006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/tropicalmed3010027","article-title":"Melioidosis: An Australian Perspective","volume":"3","author":"S Smith","year":"2018","journal-title":"Trop Med Infect Dis"},{"key":"pntd.0012631.ref007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","article-title":"Epidemiology of infections in cancer patients","volume":"161","author":"TR Zembower","year":"2014","journal-title":"Cancer Treat Res"},{"issue":"2","key":"pntd.0012631.ref008","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00006-19","article-title":"Human Melioidosis","volume":"33","author":"I Gassiep","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"pntd.0012631.ref009","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1204699","article-title":"Melioidosis","volume":"367","author":"WJ Wiersinga","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pntd.0012631.ref010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"pntd.0012631.ref011","doi-asserted-by":"crossref","first-page":"e0009060","DOI":"10.1371\/journal.pntd.0009060","article-title":"Effectiveness of a multifaceted prevention programme for melioidosis in diabetics (PREMEL): A stepped-wedge cluster-randomised controlled trial","volume":"15","author":"P Suntornsut","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0012631.ref012","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ekir.2017.09.005","article-title":"Trimethoprim+Sulfamethoxazole Reduces Rates of Melioidosis in High-Risk Hemodialysis Patients","volume":"3","author":"SW Majoni","year":"2018","journal-title":"Kidney Int Rep"},{"key":"pntd.0012631.ref013","unstructured":"Burkholderia pseudomallei prophylaxis in immunocompromised adults without HIV infection [Internet]. Therapeutic Guidelines Limited. 2019 [cited October 27, 2023]. Available from: https:\/\/tgldcdp.tg.org.au\/."},{"issue":"12","key":"pntd.0012631.ref014","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S1473-3099(21)00022-0","article-title":"The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation","volume":"21","author":"BJ Currie","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pntd.0012631.ref015","doi-asserted-by":"crossref","first-page":"e0009544","DOI":"10.1371\/journal.pntd.0009544","article-title":"Melioidosis-a disease of socioeconomic disadvantage","volume":"15","author":"J Hanson","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0012631.ref016","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/trstmh\/trab125","article-title":"The epidemiology of melioidosis in Townsville, Australia","volume":"116","author":"I Gassiep","year":"2022","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"pntd.0012631.ref017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4269\/ajtmh.18-0421","article-title":"Antibiotic Prophylaxis for Melioidosis in Patients Receiving Hemodialysis in the Tropics? One Size Does Not Fit All","volume":"99","author":"KWT Chau","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"pntd.0012631.ref018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/tropicalmed8110481","article-title":"The Epidemiological, Clinical, and Microbiological Features of Patients with Burkholderia pseudomallei Bacteraemia; Implications for Clinical Management","volume":"8","author":"C Prinsloo","year":"2023","journal-title":"Tropical Medicine and Infectious Disease"},{"key":"pntd.0012631.ref019","unstructured":"Queensland Health. Cancer Data Explorer. Brisbane: Cancer Alliance Queensland, Queensland Cancer Control Analysis Team.; 2023 [Available from: https:\/\/cancerallianceqld.health.qld.gov.au\/cancerdataexplorer\/."},{"issue":"3","key":"pntd.0012631.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005411","article-title":"The epidemiology and clinical features of melioidosis in Far North Queensland: Implications for patient management","volume":"11","author":"JD Stewart","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0012631.ref021","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","article-title":"Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"J Crawford","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"pntd.0012631.ref022","unstructured":"Management of Data and Information in Research; A guide supporting the Australian Code for the Responsible Conduct of Research Canberra: National Health and Medical Research Council, Australian Research Council and Universities Australia. Commonwealth of Australia.; 2019 [Available from: https:\/\/www.nhmrc.gov.au\/sites\/default\/files\/documents\/attachments\/Management-of-Data-and-Information-in-Research.pdf."},{"key":"pntd.0012631.ref023","unstructured":"Australian census Canberra: Australian Bureau of Statistics; 2021 [Available from: https:\/\/www.abs.gov.au\/census."},{"key":"pntd.0012631.ref024","article-title":"Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions","author":"EY Lee","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"pntd.0012631.ref025","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3201\/eid2712.211302","article-title":"Increased Incidence of Melioidosis in Far North Queensland, Queensland, Australia, 1998\u20132019","volume":"27","author":"S Smith","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"pntd.0012631.ref026","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4269\/ajtmh.18-0806","article-title":"Melioidosis in the Torres Strait Islands, Australia: Exquisite Interplay between Pathogen, Host, and Environment","volume":"100","author":"AJ Hempenstall","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"pntd.0012631.ref027","doi-asserted-by":"crossref","first-page":"e0236339","DOI":"10.1371\/journal.pone.0236339","article-title":"The applicability of commonly used predictive scoring systems in Indigenous Australians with sepsis: An observational study","volume":"15","author":"J Hanson","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"pntd.0012631.ref028","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3201\/eid2911.230951","article-title":"Clinical Manifestations and Genomic Evaluation of Melioidosis Outbreak among Children after Sporting Event, Australia","volume":"29","author":"S Smith","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"pntd.0012631.ref029","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pon.3077","article-title":"Correlates of continued smoking versus cessation among survivors of smoking-related cancers","volume":"22","author":"CJ Berg","year":"2013","journal-title":"Psychooncology"},{"issue":"2","key":"pntd.0012631.ref030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4269\/ajtmh.19-0375","article-title":"High Rates of Premature and Potentially Preventable Death among Patients Surviving Melioidosis in Tropical Australia","volume":"101","author":"J Hanson","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0012631.ref031","article-title":"The Incidence, Aetiology and Clinical Course of Serious Infections Complicating Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis in Tropical Australia","author":"C Price","year":"2024","journal-title":"Preprints"},{"issue":"3","key":"pntd.0012631.ref032","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10096-022-04542-0","article-title":"A multi-centre retrospective study of Nocardia speciation and antimicrobial susceptibility in Queensland, Australia","volume":"42","author":"BZ Sim","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"pntd.0012631.ref033","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3201\/eid2011.131315","article-title":"Foodborne illness, Australia, circa 2000 and circa 2010","volume":"20","author":"M Kirk","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pntd.0012631.ref034","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/tid.12196","article-title":"Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant","volume":"16","author":"TA Horwedel","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"pntd.0012631.ref035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/mja2.51739","article-title":"Invasive group A streptococcal disease in the Northern Territory and the impact of melioidosis antibiotic prophylaxis","volume":"217","author":"JM Birrell","year":"2022","journal-title":"Med J Aust"},{"issue":"8","key":"pntd.0012631.ref036","doi-asserted-by":"crossref","first-page":"ofae431","DOI":"10.1093\/ofid\/ofae431","article-title":"Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis","volume":"11","author":"A Bryce","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"pntd.0012631.ref037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"JW Park","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"pntd.0012631.ref038","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14397595.2020.1812834","article-title":"The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases","volume":"31","author":"T Harada","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"4","key":"pntd.0012631.ref039","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7547\/1000299","article-title":"Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report","volume":"100","author":"MR Langlois","year":"2010","journal-title":"J Am Podiatr Med Assoc"},{"key":"pntd.0012631.ref040","first-page":"2014","article-title":"A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole","author":"JP Rijal","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"3","key":"pntd.0012631.ref041","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1128\/AAC.05813-11","article-title":"Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease","volume":"56","author":"HM Soeters","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pntd.0012631.ref042","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/320532","article-title":"Resistance to Trimethoprim-Sulfamethoxazole","volume":"32","author":"GM Eliopoulos","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pntd.0012631.ref043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1071\/PY22142","article-title":"Community antibiotic management of skin infections in the Torres Strait","volume":"29","author":"A Hempenstall","year":"2023","journal-title":"Aust J Prim Health"},{"issue":"4","key":"pntd.0012631.ref044","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pathol.2018.11.015","article-title":"Increasing prevalence of methicillin-resistant Staphylococcus aureus in remote Australian communities: implications for patients and clinicians","volume":"51","author":"I Guthridge","year":"2019","journal-title":"Pathology"},{"issue":"9","key":"pntd.0012631.ref045","doi-asserted-by":"crossref","first-page":"e0034321","DOI":"10.1128\/AAC.00343-21","article-title":"Efficacy and Safety of Intravenous Lincosamide Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"65","author":"I Guthridge","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0012631.ref046","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2334-8-40","article-title":"High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa","volume":"8","author":"MF Cotton","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"6","key":"pntd.0012631.ref047","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3322\/caac.21697","article-title":"Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward","volume":"71","author":"AK Nanayakkara","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"pntd.0012631.ref048","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(03)01218-X","article-title":"Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment","volume":"4","author":"S Vento","year":"2003","journal-title":"Lancet Oncol"},{"issue":"2","key":"pntd.0012631.ref049","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal Infections Among Cancer Patients: A Population-Based Study in the United States","volume":"10","author":"Y Zheng","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"12","key":"pntd.0012631.ref050","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S1473-3099(15)00270-4","article-title":"Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study","volume":"15","author":"A Teillant","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"pntd.0012631.ref051","doi-asserted-by":"crossref","first-page":"1075593","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"A Crespin","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"pntd.0012631.ref052","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-006961","article-title":"Shortage of essential antimicrobials: a major challenge to global health security","volume":"6","author":"N Shafiq","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"7","key":"pntd.0012631.ref053","doi-asserted-by":"crossref","first-page":"e0012317","DOI":"10.1371\/journal.pntd.0012317","article-title":"Bone and joint infections due to melioidosis; diagnostic and management strategies to optimise outcomes","volume":"18","author":"P Dadwal","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012631.ref054","unstructured":"Cancer data in Australia. Canberra: Australian Institute of Health and Welfare; 2024."},{"issue":"2","key":"pntd.0012631.ref055","doi-asserted-by":"crossref","first-page":"e0494922","DOI":"10.1128\/spectrum.04949-22","article-title":"Comparison of Melioidosis Indirect Hemagglutination Assay between Three Testing Laboratories in Australia","volume":"11","author":"M Armstrong","year":"2023","journal-title":"Microbiol Spectr"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012631","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T18:31:52Z","timestamp":1730917912000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012631"}},"subtitle":[],"editor":[{"given":"T. Eoin","family":"West","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012631","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0012631","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}